A study of notifications of malformations of the central nervous system together with specialist reports in 1979 in March 1979 and arose from the need to examine critically the effectiveness of our screening programme in practice.
Patients and methods
The East Berkshire Health District provides maternity services for a population of 370 000. From March 1979 to March 1982 all pregnant women presenting before 19 weeks' gestation were offered screening for neural tube defects through maternal serum alphafetoprotein (s-AFP); 83% had maternal s-AFP concentrations determined. Of the remaining 17% comprising two groups of roughly equal numbers, half presented too late to be screened and the remainder presented early but failed to reattend for screening at 16-18 weeks. Rather fewer than 100 women each year refused the test. Most patients were monitored by a system of shared care. Patients with raised s-AFP concentrations were investigated by 22 ultrasonar scanning to exclude multiple pregnancy, to identify incorrect gestational dating, and to identify babies with anencephaly. In the absence of any cause shown by ultrasound, amniocentesis was offered and carried out either locally or at the regional unit. We ascertained the outcome of all pregnancies in East Berkshire that were at 16 weeks' gestation between 7 March 1979 and 6 March 1982. The notes of patients with raised s-AFP or who delivered babies with neural tube defects were examined with respect to timing of screening investigations, antenatal history, maternal race and weight, and precise description of fetal pathology.
S-AFP REPRODUCIBILITY
Precision calculated from repeated duplicate s-AFP estimation3 shows acceptable stability with coefficients of variation between 3% and 7%. When a specimen with a raised s-AFP was found, the assay was repeated in the next batch, usually three days later. In no case did the results differ from the mean by more than 5%. A repeat determination was made after an interval of 7-14 days on 22 volunteers. The mean rise for the 22 patients was 10 KIU/1 per 10 days: in only two cases was no increase detected after seven days. Twice in the three year period a low s-AFP did appear to follow a raised concentration found less than a week earlier. There were 35 pregnancies with raised s-AFP confirmed by ultrasound to be twins but in the outcome one of these was a discordant anencephalic fetus.
A further 44 pregnancies (21% of all raised AFPs) resulted in a defective fetus or infant: there were 32 second trimester spontaneous abortions about the time of the test and three other second trimester losses due to known causes; four were stillborn, all with severe intrauterine growth retardation; and five were liveborn, two of whom were neonatal deaths, two suffered intrauterine intraventricular haemorrhage, and one was microcephalic.
The remaining 56 delivered normal healthy full term singleton infants; of these patients, 47 had had amniocentesis as a result of the finding of raised s-AFP. Table 2 shows the pattern by year and by use of amniocentesis.
FETUSES WITH NEURAL TUBE DEFECTS
There were 52 fetuses with neural tube defects; 17 Of the 52 fetuses with neuiral tube defects, 22 were terminated as a result of the programme, one aborted spontaneously, 10 were stillborn, and 18 were liveborn. Of the liveborn, eight are known to be dead and 10 are alive. Table 4 shows the screening result, course, and present state of the survivors.
Discussion
The success of a screening programme for neural tube defects, assuming acceptability and improved outcome, depends on the proportion of pregnant women presenting and the test specificity and sensitivity. The latter depends critically on precise AFP analysis and accurate gestational dating.
S-AFP ASSAY
Reports in Europe' and in America4 recommended assays to be restricted to "certified" high volume The high incidence of neural tube defects (6 per 1000) in the unscreened population suggests strong selective factors for screening and contributes to the lower than theoretical overall percentage detected. Early in the study period the incidence of neural tube defects in the unscreened population was even higher. The proportion of non-attenders has remained almost constant at about 17%, however, whereas the proportion of neural tube defects in this group appears to have fallen over the three years of the programme, and we have no explanation for this at present.
RAISED S-AFP AND NON-NTD PATHOLOGY
Hyper s-alphafetoproteinaemia is a poor indicator of multiple pregnancy, and in only one in four cases did news of a twin pregnancy arise after ultrasonography initiated by a raised s-AFP. The value of a raised s-AFP in fields other than neural tube defects however, should not be discounted. As On the credit side, we believe that we have already substantially reduced the number of severely disabled children born in this district. Of the 10 surviving infants with spina bifida arising from the period surveyed, eight have had surgical repairs and have no residual major neurological handicap, while two children have gross handitap including hydrocephalus, paralysis of the legs, and absent bowel and bladder tone. We can, however, identify another 14 pregnancies that have been terminated for the same abnormality (12 meningomyeloceles, 2 occipito encephaloceles, table 3). No normal fetus was terminated, and all terminations of pregnancy were for true pathology. We also believe that in some instances when patients had no identifiable cause for their inappropriate hyper-alphafetoproteinaemia, the abnormal laboratory finding led to improved management and care. Finally, although probably fortuitous, it is noteworthy that no patient screened for neural tube defects and found normal during 1981 or 1982 (almost half the period surveyed) subsequently produced an abnormal fetus.
In conclusion, we recommend that: (1) Every endeavour should be made to screen the entire pregnant population, so that any mothers left unscreened are those exercising an informed choice; more publicity in GPs' surgeries and antenatal clinics may be necessary. (2) Reliable and reproducible assays for -termining AFP in serum and amniotic fluid need tU be continually maintained and quality assessment monitored. (3) An action limit of 2-8 x median for 16, 17, or 18 weeks will be satisfactory, provided that gestational age is correct + 5 days, and maternal weight is under 72 kg. (4) 
